ScienceDCVax-L and claims of 17- and 18-year glioblastoma survival
A post revisits remarks attributed to Dr. Steven Toms at a January 2023 press conference and says the treatment was still awaiting approval in September 2026.
TLDR
A September 20, 2026, post highlights long-term survival claims about DCVax-L for glioblastoma. It quotes Dr. Steven Toms as saying Dr. Linda Liau had patients 17 and 18 years out from treatment—longer than any survivors in his own experience. The post dates those remarks to a January 2023 press conference and says Toms had hoped for approval well before September 2026.
Combined views
50.1K
2 Sources, first seen 4d ago
1.5K likes
DCVax-L and claims of 17- and 18-year glioblastoma survival
A post revisits remarks attributed to Dr. Steven Toms at a January 2023 press conference and says the treatment was still awaiting approval in September 2026.